kras
Entity, reached from Hormuz.
- Evidence
- 422 documents · 170 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 9 Oct 2026
- Measured
- 13% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Fierce Pharma · 2026-10-09 · FDA’s Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data (opens the source in a new tab)
- medRxiv Oncology · 2026-10-07 · Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic r… (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-07 · Lipid acyl chain remodeling governs KRAS nanoclustering and oncogenic functions through membrane composition control (opens the source in a new tab)
- MedComm (2020) · 2026-10-06 · KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. (opens the source in a new tab)
- Arq Bras Cir Dig · 2026-10-05 · Association between KRAS gene mutation and clinicopathological factors in patients with metastatic colorectal cancer. (opens the source in a new tab)
- J Thromb Haemost · 2026-10-03 · KRAS Mutation and Venous Thromboembolism Risk in Colorectal Cancer: A Danish Population-Based Cohort Study. (opens the source in a new tab)
- Int J Cancer · 2026-10-02 · Spatial Transcriptomic Profiling Reveals a Fibroblast-Associated Extracellular Matrix Niche in KRAS G12C-Mutant Lung Adenocarcinoma Primary Tumors From Patients With Metas… (opens the source in a new tab)
- Fierce Pharma · 2026-10-02 · Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-02 · Acute Metabolic Switch by High-Dose Dehydroascorbic Acid: Rapid TCA Cycle Depletion and Early Signature of Methionine Trap within 1 Hour in KRAS-Mutant Cells (opens the source in a new tab)
- Future Oncol · 2026-10-01 · SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. (opens the source in a new tab)
What is claimed about it
- Single source: Reported by one source so far.
- KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. Single source · a claim about it
Situations it is named in
Who it moves with
- co-mentioned with colorectal cancer (135 documents)seen together
- co-mentioned with lung cancer (83 documents)seen together
- co-mentioned with g12d (74 documents)seen together
- co-mentioned with pancreatic cancer (61 documents)seen together
- co-mentioned with kras-mutant (51 documents)seen together
- co-mentioned with immunotherapy (48 documents)seen together
- co-mentioned with egfr (32 documents)seen together
- co-mentioned with braf (29 documents)seen together
- co-mentioned with solid tumors (27 documents)seen together